Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 273,092
  • Shares Outstanding, K 64,257
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,030 K
  • EBIT $ -25 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 22.08

Options Overview Details

View History
  • Implied Volatility 142.79% ( +12.82%)
  • Historical Volatility 58.96%
  • IV Percentile 75%
  • IV Rank 21.39%
  • IV High 393.78% on 12/13/24
  • IV Low 74.49% on 07/02/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 145
  • Volume Avg (30-Day) 431
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 18,759
  • Open Int (30-Day) 19,012

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +11.55%
on 03/04/25
5.25 -19.05%
on 02/11/25
-0.78 (-15.51%)
since 02/10/25
3-Month
3.77 +12.73%
on 12/18/24
8.33 -48.98%
on 12/12/24
-3.77 (-47.01%)
since 12/10/24
52-Week
1.30 +226.92%
on 04/18/24
10.00 -57.50%
on 11/13/24
+2.13 (+100.47%)
since 03/08/24

Most Recent Stories

More News
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals to Release Interim Data from Phase 1 Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals will announce interim Phase 1 trial data for soquelitinib in atopic dermatitis on December 18, 2024.Quiver AI SummaryCorvus Pharmaceuticals, Inc. will release interim data from its...

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals Publishes Preclinical Data on Soquelitinib's Potential to Modulate Tumor Immunity

Corvus Pharmaceuticals publishes preclinical data on soquelitinib, highlighting its potential in cancer immunotherapy and immune disease treatment.Quiver AI SummaryCorvus Pharmaceuticals has published...

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals Presents New Preclinical Data Supporting Soquelitinib's Efficacy in Systemic Sclerosis at ACR Convergence 2024

Corvus Pharmaceuticals presents new preclinical data on soquelitinib's efficacy against immune diseases at ACR Convergence 2024.Quiver AI SummaryCorvus Pharmaceuticals has announced preclinical data supporting...

CRVS : 4.25 (-8.01%)
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

CRVS : 4.25 (-8.01%)

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 4.90
2nd Resistance Point 4.74
1st Resistance Point 4.50
Last Price 4.25
1st Support Level 4.10
2nd Support Level 3.94
3rd Support Level 3.70

See More

52-Week High 10.00
Fibonacci 61.8% 6.68
Fibonacci 50% 5.65
Fibonacci 38.2% 4.62
Last Price 4.25
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar